Loading clinical trials...
Loading clinical trials...
A Phase I/II Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) in Relapsed/Refractory Cancers of Children and Young Adults
Conditions
Interventions
PEG- BCT-100
Locations
14
Australia
Women's & Children's Hospital
Adelaide, Australia
Queensland Children's Hospital
Brisbane, Australia
Royal Children's Hospital Melbourne
Melbourne, Australia
Perth Children's Hospital
Perth, Australia
Children's Hospital Westmead
Sydney, Australia
Sydney Children's Hospital
Sydney, Australia
Start Date
August 28, 2018
Primary Completion Date
July 22, 2022
Completion Date
July 22, 2022
Last Updated
September 2, 2022
NCT05691465
NCT05692635
NCT04929028
NCT05673200
NCT05198830
NCT05702398
Lead Sponsor
University of Birmingham
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions